$1.52
3.80% yesterday
Nasdaq, Aug 18, 10:00 pm CET
ISIN
US5560991094
Symbol
MGNX

MacroGenics, Inc. Stock price

$1.52
+0.04 2.70% 1M
-1.34 46.85% 6M
-1.73 53.23% YTD
-2.03 57.18% 1Y
-2.88 65.45% 3Y
-24.80 94.22% 5Y
-29.27 95.06% 10Y
-23.47 93.92% 20Y
Nasdaq, Closing price Mon, Aug 18 2025
-0.06 3.80%
ISIN
US5560991094
Symbol
MGNX
Industry

Key metrics

Basic
Market capitalization
$99.4m
Enterprise Value
$-54.8m
Net debt
positive
Cash
$154.1m
Shares outstanding
63.1m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
0.6 | 2.7
EV/Sales
negative | negative
EV/FCF
0.8
P/B
1.3
Financial Health
Equity Ratio
44.4%
Return on Equity
-57.7%
ROCE
-37.4%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$154.1m | $37.4m
EBITDA
$-55.7m | $-95.5m
EBIT
$-63.2m | $-173.3m
Net Income
$-55.8m | $-142.3m
Free Cash Flow
$-72.4m
Growth (TTM | estimate)
Revenue
255.6% | -75.0%
EBITDA
-131.2% | 7.3%
EBIT
-93.8% | -56.7%
Net Income
-141.0% | -112.4%
Free Cash Flow
36.4%
Margin (TTM | estimate)
Gross
89.9%
EBITDA
-36.2% | -255.1%
EBIT
-41.0%
Net
-36.2% | -380.0%
Free Cash Flow
-47.0%
More
EPS
$-0.9
FCF per Share
$-1.1
Short interest
7.9%
Employees
341
Rev per Employee
$440.0k
Show more

Is MacroGenics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,018 stocks worldwide.

MacroGenics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

13 Analysts have issued a MacroGenics, Inc. forecast:

7x Buy
54%
6x Hold
46%

Analyst Opinions

13 Analysts have issued a MacroGenics, Inc. forecast:

Buy
54%
Hold
46%

Financial data from MacroGenics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
154 154
256% 256%
100%
- Direct Costs 16 16
126% 126%
10%
138 138
279% 279%
90%
- Selling and Administrative Expenses 67 67
26% 26%
44%
- Research and Development Expense 171 171
3% 3%
111%
-56 -56
131% 131%
-36%
- Depreciation and Amortization 7.47 7.47
12% 12%
5%
EBIT (Operating Income) EBIT -63 -63
94% 94%
-41%
Net Profit -56 -56
141% 141%
-36%

In millions USD.

Don't miss a Thing! We will send you all news about MacroGenics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

MacroGenics, Inc. Stock News

Neutral
GlobeNewsWire
4 days ago
ROCKVILLE, Md., Aug. 14, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today reported financial results for the second quarter ended June 30, 2025, and highlighted recent corporate progress.
Neutral
GlobeNewsWire
5 days ago
ROCKVILLE, MD, Aug. 13, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company developing innovative antibody-based therapeutics for the treatment of cancer, today announced that effective as of August 13, 2025, Eric Risser has been appointed President, Chief Executive Officer and to the Board of Directors. Mr. Risser has served as Chief Operating ...
Neutral
Seeking Alpha
2 months ago
I maintain a tentative 'Buy' on MacroGenics, Inc., but acknowledge increased risk after the vobra duo failure and ongoing cash flow challenges. Lorigerlimab is now the lead pipeline candidate, with key phase 2 data expected in late 2025, and additional programs like MGC-026 and MGC-028 progressing. The recent royalty deal extends the cash runway, but liquidity concerns remain, and further asset...
More MacroGenics, Inc. News

Company Profile

MacroGenics, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing antibody-based therapeutics designed to modulate the human immune response for the treatment of cancer. 2. Its product pipeline includes Margetuximab, Flotetuzumab, Enoblituzumab, MGA012, MGD013, MGD019, MGD009, MGC018, and MGD007 for oncology; and MGD014 for infectious diseases. The company was founded by Scott E. Koenig, Jeffrey V. Ravetch, LeRoy E. Hood, Ruedi Aebersold, and Alan Aderem on August 14, 2000 and is headquartered in Rockville, MD.

Head office United States
CEO Scott Koenig
Employees 341
Founded 2000
Website www.macrogenics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today